Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...
Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...
Every item on this page was chosen by a Town & Country editor. We may earn commission on some of the items you choose to buy. A fashionable truth is that even the smallest adjustment to an outfit can ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...
AI-generated summary reviewed by our newsroom. Read our AI Policy. Macy’s will close its Triangle Town Center store, leaving two Triangle locations. Company cites focus on investing in stores and ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It could be the jolt of energy ...
Hosted on MSN
Cathie Wood’s ARK Investment buys 755K shares of Recursion Pharmaceuticals, Inc. (RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results